Percutaneous stent implantation to stenotic bioprosthetic valves in the pulmonary position

Carlos A. C. Pedra, MD*
Henri Justino, MD, FRCPC**
David G. Nykanen, MD, FRCPC
Glen VanArsdell, MD, FRCSC
John G. Coles, MD, FRCSC
William G. Williams, MD, FRCSC
Robert M. Freedom, MD, FRCPC
Lee N. Benson, MD, FRCPC

Background: We evaluated stent implantation across stenotic bioprosthetic pulmonary valves in 9 patients.

Methods: Nine patients (6 male patients) underwent stent implantation across stenotic bioprosthetic pulmonary valves between July 1996 and July 1999 at the Hospital for Sick Children, Toronto. Catheter intervention was indicated if echocardiography revealed Doppler estimates of right ventricular pressure of more than two thirds of systemic arterial pressure (or systolic septal flattening with an estimated gradient of >60 mm Hg across the valve prosthesis). Catheterization was performed during general anesthesia at an age (mean ± SD) of 9.3 ± 3.5 years and a weight of 32.0 ± 17.1 kg 5.9 ± 1.8 years after surgical insertion of a bioprosthetic valve in the pulmonary position: 7 patients with tetralogy of Fallot, 1 patient with congenital pulmonary stenosis-insufficiency, and 1 patient after a Rastelli operation. All had systolic septal flattening and right ventricular dilatation with moderate-to-severe pulmonary insufficiency before intervention. Fluoroscopy times were 33.1 ± 9.5 minutes. Seven patients received a single P4014 stent, and 2 received single P308 stents (Palmaz; Johnson & Johnson Interventional Systems, Warren, NJ) without significant complications.

Results: The right ventricular systemic pressure decreased acutely from 83% ± 16% to 41% ± 10% (P < .001, n = 9), and the transvalvular gradient decreased from 49.7 ± 8.5 to 11.0 ± 5.9 mm Hg (P < .001, n = 8). During the follow-up period (10.9 ± 8.1 months, n = 8), 1 patient had an unsuccessful attempt at redilation of the stent (right ventricular pressure, 60% systemic) and underwent uneventful surgical pulmonary valve replacement. None of the remaining patients had echocardiographic evidence of systolic septal flattening, and right ventricular dimensions did not change significantly.

Conclusion: Stent implantation is a safe and effective means of providing palliative relief of obstructed bioprosthetic valves in the pulmonary position and can safely delay the requirement for pulmonary valve replacement.

Surgical insertion of a bioprosthetic valve to reconstruct the right ventricular (RV) outflow tract has been used in the repair of complex cardiac defects, such as tetralogy of Fallot and transposition of the great arteries with ventricular septal defect and pulmonary stenosis.1-3 Although such valves tend to perform reasonably well in the pulmonary position,4 late stenosis caused by leaflet calcification and size mismatch as a result of body growth remain universal issues, committing the patient
to further procedures.5-7 Although surgical valve replacement can be performed at a low mortality risk,3,8 morbidity is associated with repeat sternotomy and cardiotomy, and technical difficulties arise from previous operations. Percutaneous balloon valvuloplasty has shown only marginal efficacy for relief of such obstructions.9-14 On the other hand, in the setting of RV to pulmonary artery conduits, a significant prolongation of conduit life span has been safely achieved after implantation of balloon expandable intravascular stents.15-18 In this study we report our experience with this palliative strategy to relieve obstructions in bioprosthetic valves in the pulmonary position.

Methods

Study Design

A computer database search identified 9 patients who underwent placement of intravascular stents across bioprosthetic valves in the pulmonary position between July 1996 and July 1999 at the Hospital for Sick Children, Toronto, Ontario, Canada. Data were compiled retrospectively from the hospital records, including clinic visits, echocardiograms, catheterizations, and surgical notes. In particular, the type of valve, diameter, and position were noted. Informed consent for the procedures was obtained from parents following guidelines of the Human Subject Protection Committee of the Hospital for Sick Children, University of Toronto.

Indications for Intervention

Patients with an estimated RV systolic pressure exceeding two thirds of systemic arterial pressure or a transvalvular gradient of at least 60 mm Hg, as documented with Doppler echocardiography (regardless of the presence of symptoms, such as exercise intolerance or fatigue), were referred for catheter intervention.17,18 If no tricuspid regurgitation was detected on echocardiography, systolic flattening of the interventricular septum was considered a reliable indicator of a high (>50% systemic) RV systolic pressure.19

Technique

Under general anesthesia, routine right heart hemodynamics and angiography (right ventricle and main and branch pulmonary arteries) were performed before and after stent implantation. Occasionally, to profile the valve, the lateral image intensifier was positioned slightly cranial or caudal by using the radiopaque band on the bioprosthetic valve sewing ring (Figure 1) to adjust the beam. The minimal valve opening diameter was measured angiographically in the anterior cranial-caudal and lateral views, as was the length of the main pulmonary artery segment and distance from the radiopaque ring to the RV muscular cavity. The known diameter of the angiography catheter was used to correct for magnification.

The technique of stent delivery has been described in detail elsewhere.17,18,20 Palmaz stents (Johnson & Johnson Interventional Systems, Warren, NJ) were used in all patients. In general, a complex consisting of a long sheath (Mullins type, sizes 8F to 12F; Cook, Bloomington, Ind), a stent, and a balloon (diameters 12-23 mm, lengths 3-5.5 cm; Mansfield, Boston Scientific, Watertown, Mass) was advanced percutaneously as a single unit over an 0.035-inch extrastiff guide wire (260-cm length, Amplatz Extra-Stiff, Cook) to lie across the area of stenosis within the bioprosthetic valve (usually just above the metallic valvular ring) but still within the Dacron or pericardial patch extension used for RV flow enlargement. Stent diameters (ie, balloon diameters) were chosen to be 3 or 4 mm less than the rated valve diameter to allow for the thickness of the sewing ring. As such, the stent was implanted to have a slight waist (Figure 1). The length of the stent was chosen to allow the positioning across the sewing ring and complete apposition against the valve leaflets along the main pulmonary artery wall. Once the stent was expanded and in a stable position, angiography was again performed to confirm adequate stent position.
position, no further attempts to flare the stent ends were performed. Prior balloon dilatation of the bioprosthetic valve was performed in 1 patient without any decrease in RV systolic pressure. Cefazolin (40 mg/kg per dose; maximum, 1 g) was administered intravenously at the time of catheterization and every 8 hours for a total of 3 doses. Heparin sulfate was administered in the catheterization laboratory (150 IU/kg; maximum, 5000 IU) and maintained as a continuous infusion until the following morning (10 IU·kg⁻¹·h⁻¹), with no monitoring of the activated partial thromboplastin time. At discharge, a low dose of aspirin (2.5 mg·kg⁻¹·d⁻¹; maximum, 325 mg) was prescribed for 3 to 6 months.

Follow-Up
Follow-up visits were at the referring cardiologist’s discretion but were generally scheduled every 6 months with echocardiographic evaluation. Repeat catheterization was undertaken if progressive conduit obstruction with indications for reintervention was suspected from the echocardiographic evaluation.

Statistical Analysis
All values are expressed as means ± SD or median and range, as applicable. A paired Student t test or a Mann-Whitney rank sum test was used to compare changes in intracardiac pressures and measurements before the procedure, immediately after, and at follow-up. Linear regression was used to evaluate the correlation between pressure gradients (right ventricle to pulmonary artery) obtained at echocardiography and catheterization. A Fisher exact test was used to compare changes in the septal motion before and after the procedure.

Results
Patients
Six male and 3 female patients underwent stent placement across a bioprosthetic valve in the pulmonary position at a mean age of 9.3 ± 3.5 years (range, 5.9-15.2 years; median, 7.9 years), with a mean weight of 32.0 ± 17.1 kg (range, 14.5-68.2 kg; median, 27.2 kg) and a mean body surface area of 1.1 ± 0.4 m² (range, 0.6-1.84 m²; median, 0.98 m²). Seven patients had repair of tetralogy of Fallot, 1 had a Rastelli repair for complete transposition of the great arteries with a ventricular septal defect and pulmonary stenosis, and 1 patient had complete repair of congenital pulmonary stenosis and insufficiency with closure of an atrial septal defect and patent arterial duct (Table 1). In 6 patients the valve implant was in the orthotopic position. The 3 remaining patients had a bioprosthetic pulmonary valve located within a conduit, 2 having had previous operations that involved conduits (ie, 1 Rastelli procedure [patient 9] and 1 conduit placed anterior to the native RV outflow tract [patient 5]). Both of these patients had subsequent operations, with implantation of a bioprosthetic pulmonary valve within the conduit. The third patient (patient 2) had a conventional repair of tetralogy of Fallot with an RV outflow tract patch. However, because of development of an RV outflow tract aneurysm, the patient underwent resection of the aneurysm, and a conduit was placed within the native RV outflow tract, subsequently undergoing conduit revision and then a valve implant. A Mitroflow (bovine pericardial) valve (Mitroflow International, Inc, Richmond, British Columbia, Canada) was implanted in 8 patients, and a Medtronic Intact (porcine aortic) valve (Medtronic, Minneapolis, Minn) was implanted in 1 patient. The median time between the last surgical procedure and stent implantation was 7.9 years (range, 3.8-9.2 years; mean, 5.9 ± 1.8 years). Seven patients had exercise intolerance (with fatigue), 1 had chest pain, and 1 was asymptomatic.

### TABLE 1. Patient data

<table>
<thead>
<tr>
<th>Patient No.</th>
<th>Sex</th>
<th>Diagnosis</th>
<th>Operations (age, y)</th>
<th>Type and size of valve</th>
<th>Age at catheterization (y)</th>
<th>Interval from valve implant (y)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M</td>
<td>TOF, APVS</td>
<td>TOF repair + valve implant (2.7)</td>
<td>Mitroflow 19</td>
<td>6.5</td>
<td>3.8</td>
</tr>
<tr>
<td>2</td>
<td>F</td>
<td>TOF, APVS, PAPVD to SVC</td>
<td>TOF repair (monocusp valve) (0.2), resection of RVOT and conduit insertion (0.4), conduit revision (1.8), valve implant (2.2)</td>
<td>Mitroflow 19</td>
<td>6.0</td>
<td>3.8</td>
</tr>
<tr>
<td>3</td>
<td>M</td>
<td>TOF, PAPVD to SVC, LSVC to CS</td>
<td>BTS (0.2), TOF repair (2.5), valve implant and resection RVOT aneurysm (4.5)</td>
<td>Mitroflow 25</td>
<td>10.3</td>
<td>5.8</td>
</tr>
<tr>
<td>4</td>
<td>F</td>
<td>TOF, AVSD</td>
<td>Total repair + valve implant (2.5)</td>
<td>Medtronic 19</td>
<td>7.9</td>
<td>5.4</td>
</tr>
<tr>
<td>5</td>
<td>M</td>
<td>TOF, absent LPA</td>
<td>BTS (0.1), total repair to RPA with conduit and preservation of native RVOT and valve implant (5.3)</td>
<td>Intact 23</td>
<td>14.5</td>
<td>9.2</td>
</tr>
<tr>
<td>6</td>
<td>M</td>
<td>Congenital PI/PS, PDA, ASD</td>
<td>PDA ligation and valve implant (0.02)</td>
<td>Mitroflow 19</td>
<td>7.9</td>
<td>7.9</td>
</tr>
<tr>
<td>7</td>
<td>F</td>
<td>TOF, AVPS</td>
<td>TOF repair (0.16), valve implant (0.4)</td>
<td>Mitroflow 19</td>
<td>5.8</td>
<td>5.4</td>
</tr>
<tr>
<td>8</td>
<td>M</td>
<td>TOF, APVS</td>
<td>TOF repair and valve implant (4.4)</td>
<td>Mitroflow 21</td>
<td>9.7</td>
<td>5.3</td>
</tr>
<tr>
<td>9</td>
<td>M</td>
<td>TGA, VSD, PS</td>
<td>Rastelli repair (5.0) and valve implant (8.7)</td>
<td>Mitroflow 21</td>
<td>15.2</td>
<td>6.5</td>
</tr>
</tbody>
</table>

**TOF:** Tetralogy of Fallot; **APVS:** absent pulmonary valve syndrome; **PAPVD:** partial anomalous pulmonary venous drainage; **SVC:** superior vena cava; **RVOT:** right ventricular outflow tract; **LSVC:** left superior vena cava; **CS:** coronary sinus; **BTS:** Blalock-Taussing shunt; **AVSD:** atrioventricular septal defect; **LPA:** left pulmonary artery; **RPA:** right pulmonary artery; **PI:** pulmonary insufficiency; **PS:** pulmonary stenosis; **PDA:** patent ductus arteriosus; **ASD:** atrial septal defect; **TGA:** transposition of the great arteries; **VSD:** ventricular septal defect.
Obtained by means of catheterization (patients awake), did not show a correlation with those.

Gradients, detected by means of echocardiography (with whom the RV/systemic arterial pressure ratio was 0.9 during tricuspid regurgitation jet) was only possible in 5 patients, in the remainder. RV systolic pressure estimate (by velocity of 2 patients, and trivial or mild regurgitation was present in 15.9 mm Hg (n = 11005). Calci

Immediate Results

Mild systolic RV dysfunction (assessed qualitatively) was present in 3 patients.

On echocardiography, performed at a median of 3 months (range, 0.5-12 months) before the stent procedure, all patients had significant pulmonary regurgitation (3 moderate and 6 severe), increased RV end-diastolic dimensions corrected for body surface area (mean, 146% ± 35%), and abnormal septal motion with flattening in systole. The mean peak instantaneous gradient across the valve was 74.7 ± 15.9 mm Hg (n = 9). Tricuspid regurgitation was absent in 2 patients, and trivial or mild regurgitation was present in the remainder. RV systolic pressure estimate (by velocity of tricuspid regurgitation jet) was only possible in 5 patients, in whom the RV/systemic arterial pressure ratio was 0.9 ± 0.2. Gradients, detected by means of echocardiography (with patients awake), did not show a correlation with those obtained by means of catheterization (r = 0.1, P = .79). Mild systolic RV dysfunction (assessed qualitatively) was present in 3 patients.

TABLE 2. Immediate results after stent implantation

<table>
<thead>
<tr>
<th></th>
<th>Before</th>
<th>After</th>
<th>Change (%)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>RV-PA gradient (mm Hg)</td>
<td>49.7 ± 5.9</td>
<td>11.0 ± 5.9</td>
<td>−78.9 ± 11.1</td>
<td>≤.001 (n = 8)*</td>
</tr>
<tr>
<td>(range 38-64)</td>
<td>(range 2-20)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RVp (mm Hg)</td>
<td>74.3 ± 9.8</td>
<td>39.6 ± 8.5</td>
<td>−46.6 ± 9.9</td>
<td>≤.001 (n = 9)*</td>
</tr>
<tr>
<td>(range 56-90)</td>
<td>(range 30-56)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sp (mm Hg)</td>
<td>91.8 ± 12.1</td>
<td>97.0 ± 10.9</td>
<td>6.9 ± 15.8</td>
<td>.275 (n = 9)*</td>
</tr>
<tr>
<td>(range 77-116)</td>
<td>(range 80-115)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RVp/Sp ratio</td>
<td>0.83 ± 0.16</td>
<td>0.41 ± 0.10</td>
<td>−49.5 ± 9.5</td>
<td>≤.001 (n = 9)*</td>
</tr>
<tr>
<td>(range 0.48-1.08)</td>
<td>(range 0.26-0.56)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RVedp (mm Hg)</td>
<td>10.8 ± 5.4</td>
<td>9.3 ± 3.2</td>
<td>−4.7 ± 20.5</td>
<td>.5 (n = 9)*</td>
</tr>
<tr>
<td>(range 5-22)</td>
<td>(range 6-16)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MPAp systolic (mm Hg)</td>
<td>24.7 ± 4.2</td>
<td>27.2 ± 5.0</td>
<td>8.0 ± 7.9</td>
<td>.27 (n = 8)*</td>
</tr>
<tr>
<td>(range 18-30)</td>
<td>(range 22-36)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AP diameter (mm)</td>
<td>Median 10</td>
<td>Median 15</td>
<td>Median 35.4</td>
<td>≤.001 (n = 8)†</td>
</tr>
<tr>
<td>(range 5-12)</td>
<td>(range 11-16)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lat diameter (mm)</td>
<td>Median 10</td>
<td>Median 15.8</td>
<td>Median 2.8</td>
<td>≤.001 (n = 8)†</td>
</tr>
<tr>
<td>(range 8-13)</td>
<td>(range 12-17)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

RV, Right ventricle; PA, pulmonary artery; RVp, right ventricular pressure; Sp, systemic arterial pressure; RVedp, right ventricular end-diastolic pressure; MPAp, main pulmonary artery pressure; AP, anteroposterior; Lat, lateral.

*By t test.
†By Mann-Whitney rank sum test.

Follow-Up Results

One patient was lost to follow-up. Mean follow-up (visits included clinical and echocardiographic examination) was 10.9 ± 8.1 months (range, 1-24 months; median, 12
months). Patient 2 had a repeat catheterization 1 year after the index procedure. RV systolic pressure was 60% of the systemic arterial pressure during general anesthesia. Even though there was no localized area of stenosis within the stent (P308), it was dilated with a 12-mm-diameter balloon, and no significant increase in stent diameter or decrease in the RV/systemic pressure ratio occurred. Because it was believed that the child had outgrown the size of the valve implant, the patient subsequently underwent an uncomplicated pulmonary valve replacement with insertion of a 23-mm Hancock valve (Medtronic, Inc) at the age of 8 years (14 months after the index stent implantation procedure). The stent was cut across with heavy scissors, and the valve was removed by using conventional approaches for valve replacement.

The 7 other patients available for follow-up reported a subjective improvement in exercise tolerance and activity level after stent implantation. On echocardiography at most recent follow-up, all patients had, as anticipated, free pulmonary insufficiency, and RV end-diastolic dimensions corrected for body surface area were similar to those before implantation (mean, 143% ± 37%; P = .88). Septal flattening in systole disappeared in all patients (P < .001). The mean peak instantaneous gradient across the valve was 31.7 ± 9.6 mm Hg (n = 7), and the RV/systemic arterial pressure ratio, available in 5 patients, was 0.51 ± 0.12. No patient had more than mild tricuspid regurgitation. RV function was qualitatively mildly reduced in 1 patient and normal in the remaining 6 patients. No endarteritis occurred in the follow-up period. There were no stent fractures or embolizations during the follow-up period.

Discussion

The experimental use of balloon expandable stents to relieve obstructions within right heart valved conduits was first described by Almagor and colleagues.21 Subsequent clinical studies from this and other institutions have demonstrated the safety and efficacy of this palliative procedure, postponing the requirement for surgical conduit replacement.15,18,22 However, the role of this palliative approach to specifically relieve stenosis within a bioprosthetic valve has not been reviewed.

Differences in the mechanism of late bioprosthetic valve dysfunction and obstruction within homograft (tissue-valved) conduits might explain some of the observations in this study. Calcification and thrombosis of the commissures result in stenosis by holding the rigid cusps in a semiopened position, which is a common late finding after valve insertion.23 In addition, valve incompetence caused by thrombosis of the valve sinuses with adherence of the cusp tissue to the adjacent wall is also frequently present.23 Because of obscure reasons, calcium deposition with progressive valve degeneration is more pronounced in children than in adults, further shortening the longevity of such valves.4-7 Contrary to these observations in bioprosthetic valves, conduit obstruction appears to be due to an internal fibrous peel formation, with or without concomitant valve stenosis23 or retraction of the patch extension to the RV free wall. Because conduits are longer and located in nonanatomic positions beneath the sternum, they are also more prone to compression and kinking.16,18,23 In this series calcification and fixation of the valves in a semiopened position with reduced mobility and variable degree of fusion of the leaflets to the adjacent wall were demonstrated on angiography in all patients. The more posterior position of the valve implant similarly decreases the risk of stent fracture caused by external compression. Meticulous attention to positioning, stent deployment across the area of stenosis at the level of the leaflets but still within the Dacron or pericardial extension, and avoidance of stent contact with the heart are crucial to prevent fractures with subsequent fragment embolization. Additionally, flaring the ends of the stent was not necessary to secure the stent in a stable position.

Because stenosis within bioprosthetic valves is a more localized phenomenon,24 stent implantation optimally relieves the obstructive area, reducing the outflow gradient. As such, the immediate results were good, despite the presence of calcium deposits within the leaflets or thrombus within the sinuses. In contrast, results might not be as satisfactory in conduits affected by a diffuse calcified fibrous peeling, external compression, or kinking.16,18

This palliative procedure is not intended as a long-term solution to the problem of RV outflow tract obstruction. Its goal is to provide a reliable, safe, easily applied method to reduce RV pressure, avoiding the requirement of early reoperation. In this series 1 patient required valve replacement 14 months after the index stent procedure because the child had outgrown the size of the stent (limited by the diameter of the bioprosthetic valve implant). Accordingly, from this experience, in the absence of a discrete lesion within the stent or a newly acquired more distal obstruction, surgical replacement is recommended rather than stent redilation.18 The remaining 7 patients continue to be asymptomatic and benefit from obstruction relief with preserved RV systolic function and RV systolic pressures of less than 50% of systemic levels.

Because significant pulmonary insufficiency was already present in all patients before stent implantation, worsening of preexisting volume overload was not an issue. In this regard, RV end-diastolic dimensions have not significantly increased during follow-up, and free pulmonary insufficiency in the absence of pressure overload appears to be well tolerated. Free pulmonary insufficiency is unlikely to cause RV failure over a short period of time, particularly if the ventricle has restrictive physiologic characteristics, as is the case in many postoperative patients with tetralogy of Fallot.25 However, it might be poorly tolerated if there are
additional residual lesions, such as distal pulmonary artery stenoses.26 Therefore accurate angiographic diagnosis and aggressive treatment of such distal lesions is mandatory at the time of stent placement.

Although no significant complications occurred in this series, compression of a coronary artery is a potential problem that might complicate the procedure, especially when the underlying anatomy is accompanied by preexisting coronary abnormalities.27 Although this palliative technique has limited application in the small infant, it might be used under special circumstances as a rescue measure.28

In conclusion, this review demonstrates the feasibility, safety, and efficacy of stent implantation across stenotic bioprosthesis in the pulmonary position. The localized obstruction seen at the level of the leaflets, although fixed and calcified, responds well to stent implantation, allowing postponement of reoperation with good clinical tolerance at short-term follow-up.

This study is limited by a small cohort with a relatively short follow-up period. A larger study involving longer follow-up and more objective measures of cardiovascular performance before and after intervention (i.e., exercise testing) and measures of RV volumes would also aid in assessing the effect of this palliative strategy on RV function.

References